| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
|
| | Gantenerumab Basic information |
| Product Name: | Gantenerumab | | Synonyms: | Gantenerumab;Research Grade Gantenerumab(DHC12503);Gantenerumab (anti-Amyloid Beta);Research Grade Gantenerumab;Indole-3-carboxaldehyde- 13 C 3 | | CAS: | 1043556-46-2 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Gantenerumab Structure]() |
| | Gantenerumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Gantenerumab Usage And Synthesis |
| Uses | Gantenerumab is a monoclonal antibody for the treatment of Alzheimer's disease being developed by Hoffmann-La Roche pharmaceuticals. | | in vivo | Gantenerumab (20 mg/kg; intravenous injection; once a week; 5 months) has a protective effect in PS2APP transgenic mice and can reduce the number of Aβ amyloid plaques[1]. | Animal Model: | PS2APP transgenic mice by administering a single anti-CD4 injection[1] | | Dosage: | 20 mg/kg | | Administration: | Intravenous injection; once a week; 5 months | | Result: | Reduced the number of Aβ amyloid plaques in PS2APP mice compared with vehicle controls. Specifically, in the hippocampus, neocortex, and thalamus, the plaque numbers were significantly reduced by 36%, 40%, and 70% respectively.
Efficiently reduced the number of smaller plaques.
Did not cause neurological or locomotor deficits.
|
|
| | Gantenerumab Preparation Products And Raw materials |
|